Symrise AG (ETR:SY1)
Germany · Delayed Price · Currency is EUR | Market Cap | 12.19B +11.6% |
| Revenue (ttm) | 4.91B -1.4% |
| Net Income | 246.08M -51.5% |
| EPS | 1.77 -51.3% |
| Shares Out | 136.78M |
| PE Ratio | 50.39 |
| Forward PE | 21.57 |
| Dividend | 1.25 (1.40%) |
| Ex-Dividend Date | May 7, 2026 |
| Volume | 493,305 |
| Open | 91.08 |
| Previous Close | 91.86 |
| Day's Range | 88.76 - 91.54 |
| 52-Week Range | 64.70 - 95.00 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 95.39 (+7.06%) |
| Earnings Date | Jul 30, 2026 |
About Symrise AG
Symrise AG operates as a supplier of fragrances, flavorings, cosmetic base materials and active ingredients, and functional ingredients and solutions in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America. It operates in two segments, Taste, Nutrition & Health; and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and product solutions used in the production of food and beverages; savory flavors; sweets, chocolate, chewing gum, baked goods, cereals, ice cream, milk, yogurt and mi... [Read more]
Financial Performance
In 2025, Symrise AG's revenue was 4.93 billion, a decrease of -1.39% compared to the previous year's 5.00 billion. Earnings were 249.33 million, a decrease of -47.86%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SY1 stock is "Buy." The 12-month stock price target is €95.39, which is an increase of 7.06% from the latest price.
News
Symrise Q2 Earnings Call Highlights
Symrise ETR: SY1 reported first-half 2026 sales of €2.539 billion and organic growth of 2%, as a stronger second quarter offset a slight organic sales decline in the first quarter. The flavor and frag...
Symrise AG Earnings Call Transcript: Q2 2026
H1 2026 saw 2% organic sales growth to €2.539 billion, with strong cash generation and resilient margins despite higher costs. North America and Asia Pacific led growth, while transformation initiatives and portfolio optimization continued. Guidance for 2026 is reaffirmed, with a focus on efficiency and innovation.
Symrise AG Quarterly report: Q2 2026
Symrise AG has published its Q2 2026 quarterly earnings report on July 30, 2026.
Symrise AG Earnings release: Q2 2026
Symrise AG released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Symrise AG Slides: Q2 2026
Symrise AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Symrise beats sales expectations on strong North America, Asia demand
German flavour and fragrance maker Symrise reported second-quarter organic sales growth above market expectations on Thursday, helped by stronger demand in North America and Asia-Pacific.
Symrise H1 Profit, Sales Decline; Confirms FY Outlook
HOLZMINDEN (dpa-AFX) - Symrise AG (SYIEF.PK), a Germany-based flavors, fragrances and cosmetic ingredients manufacturer, on Thursday reported lower first-half 2026 profit.Adjusted EBITDA decreased...
EQS-CMS: Symrise AG: Release of a capital market information
EQS Post-admission Duties announcement: Symrise AG / Announcement corresponding to Art. 5 para. 1 lit. b), para. 3 of Regulation (EU) No 596/2014 in its current version and Art. 2 para. 3 of Delegated...
Symrise To Buy Floral Concept For Undisclosed Sum
HOLZMINDEN (dpa-AFX) - Symrise AG (SYIEF.PK, SYIEY.PK, SY1.DE), a German chemicals company, said that it has signed a put option deal to acquire Floral Concept, a French natural fragrance ingredie...
Symrise AG Earnings Call Transcript: Q1 2026
Q1 2026 saw a slight organic sales decline but outperformed expectations, with strong growth in key segments and regions offsetting EMEA and Scent & Care weakness. Full-year guidance is reaffirmed, with sequential improvement and margin expansion expected.
Symrise AG Earnings release: Q1 2026
Symrise AG released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Symrise AG Slides: Q1 2026
Symrise AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Symrise AG Earnings Call Transcript: Q4 2025
2025 saw resilient organic growth, record profitability, and strong cash flow despite FX and market headwinds. Strategic transformation, portfolio optimization, and efficiency gains drove margin expansion, while 2026 guidance remains prudent amid macro uncertainty, with growth expected to accelerate in H2.
Symrise AG Annual report: Q4 2025
Symrise AG has published its Q4 2025 annual report on March 4, 2026.
Symrise AG Earnings release: Q4 2025
Symrise AG released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Symrise AG Slides: Q4 2025
Symrise AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
Symrise AG Earnings release: Q4 2025
Symrise AG released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Symrise AG Slides: Q4 2025
Symrise AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
Symrise AG Earnings Call Transcript: Q3 2025
Q3 2025 saw 1.4% organic sales growth, with strong performance in EMEA and food & beverage, but softness in North America and Latin America. Full-year growth guidance was lowered to 2.3%-3.3% amid macro headwinds, while cost savings and margin targets remain on track.
Symrise AG Earnings release: Q3 2025
Symrise AG released its Q3 2025 earnings on October 28, 2025, summarizing the period's financial results.
Symrise AG Slides: Q3 2025
Symrise AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 28, 2025.
Symrise and Aplantex Confirm an Agreement to Establish a Partnership
MONTREAL--(BUSINESS WIRE)--Symrise AG ("Symrise") and Aplantex Bio ("Aplantex") agree on a partnership covering new technologies for accessing plant-based molecules as raw material once the molecules ...
Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP
HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through a...